VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of a new clinical study demonstrating the significant prognostic value of its Nu.Q ® Cancer Assay in newly diagnosed lung cancer patients, which could help clinicians identify patients' likely outcomes and personalize treatment selection accordingly. The clinical paper entitled " Prognostic value of circulating H3K27Me3-nucleosomes in newly diagnosed lung cancer patients: Real-world evidence 1 " has been written in conjunction with researchers and clinicians at the Hospices Civils de Lyon (HCL), France's second largest university hospital system, and is currently under peer review. Dr Andrew Retter, Medical Consultant, Volition said: "Nu.Q ® Cancer represents a significant advancement in lung cancer patient management, offering clinicians an additional tool to enhance precision in treatment selection and monitoring and is a test we envisage will be used routinely in the clinic once approved. "We have worked closely with the Lyon team over several years to develop the strong scientific and clinical evidence to support the use of Nu.Q ® in the management of cancer patients. These results indicate that measuring methylated nucleosome biomarker levels with the Nu.Q ® test, at Non Small Cell Lung Cancer diagnosis, can provide valuable information about survival, progression-free survival and, crucially, enhance the identification of patients who may benefit from curative care 1-4 . "The integration of epigenetic biomarkers, such as circulating H3K27Me3-nucleosome, into personalized medicine frameworks holds great promise for refining patient stratification and treatment selection. The test is simple to complete and easy to implement, the new information helps to empower bedside clinicians and their patients to make better informed decisions on treatments and planning future care together." Frederic Wuilque...